期刊文献+

局部无进展生存评价射波刀治疗外周型肺肿瘤局部疗效价值 被引量:5

Value of local progression-free survival for evaluating local outcome of peripheral lung cancer treatedby cyberknife
原文传递
导出
摘要 目的探讨局部无进展生存(LPFS)评价射波刀治疗外周型肺肿瘤局部远期疗效的价值。方法同顾分析射波刀治疗肺转移瘤或原发瘤患者81例资料,其中原发肺肿瘤43例43个病灶,肺转移瘤38例47个病灶。58例63个病灶接受60Gy分3次治疗(20Gy/次),23例27个病灶接受54Gy分3次治疗(18Gy/次)。以近期疗效和LPFS为观察指标,Logistic法分析LPFS对局部远期疗效的预测作用。结果近期疗效评价后全组63%病灶需后续复查中再评价,随时间延长需冉评价病灶逐渐减少,且以6个月至2年减少最为迅速。再次疗效评价对后续随访疗效评价均有预测作用,但随时间延长预测作用逐渐减弱。结论LPFS是射波刀治疗局部有效的早期原发肺肿瘤或肺转移瘤可推荐的局部疗效评价指标,且对局部远期疗效也有预测价值。 Objective To investigate the value of local progression-free survival (LPFS) for evaluating the local long-term outcome of peripheral lung cancer treated by eyberknife. Methods Retrospective analysis was performed on the clinical records of 81 cyberknife-treated lung cancer patients (90 loci ) , including 43 primary lung cancer patients (43 foei ) and 38 metastatic lung cancer patients (47 loci). Of all the patients, 58(63 loci) were treated at a dose of 60 Gy/3 fractions (20 Gy/fraetion), and 23(27 foci) at a dose of 54 Gy/3 fractions (18 Gy/fraction). The short-term treatment outcome and LPFS were used as the indices for observation;a logistic regression was used for analyzing the predictive value of LPFS for local long-term treatment outcome. Results After the evaluation of short-term treatment outcome, 63% of all the foci needed further evaluation. As the follow-up lasted, the number of loci which needed further evaluation decreased, most rapidly during O. 5--2 years after treatment. Re-evaluation results had predictive value for the treatment outcome in the subsequent follow-up, but the predictive value declined as the follow-up lasted. Conclusions LPFS is a recommendable index for evaluating the local outcome of primary or metastatic lung cancer treated by cyberknife, and it also has predicative value for local long-term treatment outcome.
出处 《中华放射肿瘤学杂志》 CSCD 北大核心 2013年第2期115-117,共3页 Chinese Journal of Radiation Oncology
关键词 肺肿瘤/放射疗法 放射疗法 射波刀 局部无进展生存 疗效评价 Lung neoplasms/radiotherapy Radiotherapy, Cyberknife Local progression free survival Treatment outcome evaluation
  • 相关文献

参考文献17

  • 1Mintz A, Heron DE. CyberKnife (R) robotic stereotactic radiosurgery and stereotactie body radiation therapy. Technol Cancer Res Treat, 2010,9 : 539-540.
  • 2Gibbs IC, Loo BW Jr. CyberKnife stereotactic ablative radiotherapy fbr lung tumors. Tcchnol Cancer Res Treat,2010,9: 589-596.
  • 3Nnmura R, Suzuki I. CyberKnife radiosurgery present status and future prospect. Brain Nerve,2011,63 : 195-202.
  • 4Bibault JE, Prevost B, Dansin E, et al. Stereotaetie radiotherapy for lung cancer: non-invasive real-time tumor tracking. Cancer Radioth er, 2010,14 : 690 -697.
  • 5Nishino M, Jagannathan JP, Ramaiya NH, et al. Revised RECIST guideline version 1.1 : what oncologists want to know and what radiologists need to know. Am J Roentgenol,2010,195:281-289.
  • 6Nishino M, Jackman DM, Hatabu H, et al. New response evaluation criteria in solid tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. Am J Roentgeno1,2010,195 :221-228.
  • 7Chalian H, Tre HGI Horowitz JM, et al. Radiologie assessment of response to therapy: comparison of RECIST versions 1. 1 and 1.0. Radiographies,2011,31:2093-2105.
  • 8Binns DS, Pirzkall A, Yu W, et al. Compliance with PET acquisition protocols for therapeutic monitoring nf erlotinib therapy in an international trial for patients with non-small cell lung cancer. Eur J Nncl Med Mol hnazin.2011.38:642-650.
  • 9Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST:evolving considerations for PET response criteria in solid tumors. J Nucl Meal,2009,50 : 122-150.
  • 10Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid turnouts: revised RECIST guideline ( version 1.1 ). Eur J Cancer,2009,45:228-247.

同被引文献26

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部